Literature DB >> 15834901

The transport of chemicals in semen.

Leah Klemmt1, Anthony R Scialli.   

Abstract

Three mechanisms have been proposed for exposure of the conceptus to chemicals in semen: access of chemicals to the maternal circulation after absorption from the vagina, direct chemical exposure of the conceptus following transport from the vagina to the uterine cavity, and delivery to the egg and subsequent conceptus of chemical bound to the sperm cell. We review published data for each of these three mechanisms. Human seminal fluid chemical concentrations are typically similar to or lower than blood concentrations, although some antimicrobial agents achieve higher concentrations in semen than in blood. Vaginal absorption of medications has been shown to occur, although the vehicles in which these medications are delivered to the vagina may maintain contact with the vaginal epithelium to a greater extent than does semen. Assuming total absorption of a seminal dose of a chemical with a high semen:blood concentration ratio, distribution within the recipient woman would result in a blood concentration at least three orders of magnitude lower than that in the man. Direct delivery of seminal chemicals into the uterine cavity of humans has not been shown to occur, although it may occur in species such as the rat in which seminal fluid has access to the uterine cavity. Chemicals in or on human sperm cells have been demonstrated with respect to tetracycline and cocaine in vitro and aluminum, lead, and cadmium in vivo. The in vitro cocaine study offers sufficiently quantitative data with which to predict that oocyte concentrations would be five orders of magnitude lower than blood concentrations associated with cocaine abuse, assuming a maximally cocaine-bound sperm were capable of fertilizing. Thus, even using liberal assumptions about transmission of chemicals in semen or sperm, predicted exposure levels of a pregnant woman or of the conceptus are three or more orders of magnitude lower than blood concentrations in the man whose semen is the putative vehicle for chemical transport.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834901     DOI: 10.1002/bdrb.20031

Source DB:  PubMed          Journal:  Birth Defects Res B Dev Reprod Toxicol        ISSN: 1542-9733


  12 in total

1.  Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.

Authors:  Lindsay B Avery; Jennifer L VanAusdall; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2012-11-19       Impact factor: 3.922

2.  An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners.

Authors:  Winnie Sohn; Edward Lee; Martin K Kankam; Ogo Egbuna; Graeme Moffat; Jeanine Bussiere; Desmond Padhi; Eric Ng; Sandeep Kumar; J Greg Slatter
Journal:  Br J Clin Pharmacol       Date:  2015-12-05       Impact factor: 4.335

3.  Seminal plasma enhances cervical adenocarcinoma cell proliferation and tumour growth in vivo.

Authors:  Jason R Sutherland; Kurt J Sales; Henry N Jabbour; Arieh A Katz
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

4.  Clinical trial considerations on male contraception and collection of pregnancy information from female partners.

Authors:  Maria Longauer Banholzer; Heinrich Buergin; Christoph Wandel; Georg Schmitt; Elmar Gocke; Richard Peck; Thomas Singer; Theresa Reynolds; Marie Mannino; Jonathan Deutsch; Lucette Doessegger
Journal:  J Transl Med       Date:  2012-06-21       Impact factor: 5.531

Review 5.  The regulation of inflammatory pathways and infectious disease of the cervix by seminal fluid.

Authors:  Anthonio Adefuye; Arieh Anthony Katz; Kurt Jason Sales
Journal:  Patholog Res Int       Date:  2014-08-11

Review 6.  The Metal Neurotoxins: An Important Role in Current Human Neural Epidemics?

Authors:  Keith Schofield
Journal:  Int J Environ Res Public Health       Date:  2017-12-05       Impact factor: 3.390

7.  Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod.

Authors:  Olivier J David; Amy Berwick; Nicole Pezous; Michael Lang; Klaus Tiel-Wilck; Tjalf Ziemssen; Peng Li; Hisanori Hara; Robert Schmouder
Journal:  Clin Pharmacol Drug Dev       Date:  2017-12-19

Review 8.  Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease.

Authors:  Yong Eun Park; Tae Oh Kim
Journal:  World J Mens Health       Date:  2019-03-22       Impact factor: 5.400

9.  Birth Control in Clinical Trials: Industry Survey of Current Use Practices, Governance, and Monitoring.

Authors:  J Stewart; W J Breslin; B K Beyer; K Chadwick; L De Schaepdrijver; M Desai; B Enright; W Foster; J Y Hui; G J Moffat; B Tornesi; K Van Malderen; L Wiesner; C L Chen
Journal:  Ther Innov Regul Sci       Date:  2015-10-08       Impact factor: 1.778

10.  Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update.

Authors:  Maria Longauer Banholzer; Christoph Wandel; Paul Barrow; Marie Mannino; Georg Schmitt; Melanie Guérard; Lutz Müller; Gerard Greig; Kenjie Amemiya; Richard Peck; Thomas Singer; Lucette Doessegger
Journal:  Clin Transl Med       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.